Compass Pathways to Attend TD Cowen Healthcare Conference
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Feb 24 2026
0mins
Should l Buy CMPS?
Source: Businesswire
- Conference Participation: Compass Pathways plc will attend the TD Cowen 46th Annual Healthcare Conference in Boston from March 2-4, 2026, and participate in a fireside chat on March 3 at 10:30 AM ET, showcasing its innovations in mental health.
- Live Webcast: The event will be accessible via a live audio webcast from the 'Events' page in the Investors section of the Compass website, with a replay available for 30 days post-event, ensuring investors can stay informed.
- Innovative Treatment: Compass Pathways is advancing mental health innovation through its investigational COMP360 synthetic psilocybin treatment, which has received Breakthrough Therapy designation from the FDA, indicating its potential in treating treatment-resistant depression.
- Global Vision: The company's mission is to enhance the lives of patients with serious mental health conditions, promoting a new paradigm where mental health signifies not just the absence of illness but the ability to thrive, reflecting its forward-thinking and commitment to the industry.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy CMPS?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on CMPS
Wall Street analysts forecast CMPS stock price to rise
7 Analyst Rating
6 Buy
1 Hold
0 Sell
Strong Buy
Current: 6.860
Low
8.00
Averages
18.43
High
40.00
Current: 6.860
Low
8.00
Averages
18.43
High
40.00
About CMPS
Compass Pathways plc is a United Kingdom-based biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health. The Company is engaged in treating mental health conditions focused on rapid and durable responses through the development of its investigational COMP360 psilocybin treatment. COMP360 is its psilocybin formulation that includes its pharmaceutical-grade polymorphic crystalline psilocybin, optimized for stability and purity. The Company’s initial focus is on treatment-resistant depression (TRD), comprising patients who are inadequately served by the current treatment paradigm. It commenced its Phase III program evaluating its COMP360 psilocybin treatment in TRD. In addition, the Company has ongoing Phase II trials in PTSD and anorexia nervosa. It also provides support to research institutions conducting investigator-initiated studies with COMP360 psilocybin in areas of serious unmet need.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Helus Pharma Advances New Drug for Anxiety Treatment
- Clinical Trial Progress: Helus Pharma's Phase 2 signal detection study for HLP004 showed that among 36 patients, those receiving 20 mg achieved a mean HAM-A score reduction of 10.4 points (p<0.0001) at six weeks, indicating significant efficacy and potential for new treatment options for anxiety patients.
- Strong Market Demand: The global economy loses over $1 trillion annually due to depression and anxiety, with approximately 30% of patients suffering from treatment-resistant depression, driving the need for novel rapid-acting therapies, which Helus Pharma aims to address.
- Sufficient Financial Support: As of December 31, 2025, Helus Pharma reported $195.1 million in cash, providing ample resources to support the ongoing advancement of its multi-asset clinical pipeline, ensuring the company maintains a competitive edge in a challenging market.
- Strengthened Leadership: Helus Pharma recently appointed former Pfizer Chief Medical Officer Freda Lewis-Hall to its Board of Directors and as Chair of the Scientific Advisory Committee, leveraging her extensive industry experience to further enhance the company's scientific development and market strategy.
See More
Helus Pharma Advances Mental Health Treatments with Promising Phase 2 Results
- Clinical Trial Progress: Helus Pharma's Phase 2 signal detection study for HLP004 showed that patients receiving the 20 mg dose achieved a mean HAM-A score reduction of 10.4 points (p<0.0001) at six weeks, indicating significant efficacy and potential as an adjunctive treatment for generalized anxiety disorder.
- Strong Market Demand: The global economy loses over $1 trillion annually due to depression and anxiety, with approximately 30% of major depressive disorder patients being treatment-resistant, driving urgent demand for novel therapeutic mechanisms that Helus Pharma aims to address.
- Sufficient Financial Support: As of December 31, 2025, Helus Pharma reported $195.1 million in cash, ensuring continued advancement across its multi-asset clinical pipeline and safeguarding its research activities in the mental health sector from financial constraints.
- Enhanced Leadership: The appointment of Dr. Freda Lewis-Hall to Helus Pharma's Board and as Chair of the Scientific Advisory Committee, leveraging her extensive experience at Pfizer, is expected to provide crucial guidance for the company's scientific development and market strategy.
See More
Helus Pharma's Psychedelic Drug Achieves Phase 3 Success
- Clinical Trial Breakthrough: Helus Pharma's SPL026 demonstrated significant efficacy in a randomized controlled trial for treatment-resistant depression, with a MADRS score difference of -7.35 (p=0.023) among 34 participants, providing clinical proof-of-concept that could shift regulatory and investor perspectives on psychedelic applications in psychiatry.
- Production Quota Increase: The DEA raised the 2026 psilocybin production quota by 67%, creating larger market opportunities for companies like Helus Pharma and accelerating their research and development efforts in psychedelic therapies.
- Strong Financial Backing: As of December 31, 2025, Helus Pharma reported $195.1 million in cash, ensuring continued advancement of its multi-asset clinical pipeline, particularly for key assets like HLP003 and HLP004.
- Optimistic Future Outlook: HLP003 has shown a 100% response rate and 71% remission rate in two pivotal Phase 3 studies, with topline data expected in Q4 2026, further solidifying Helus Pharma's market position in depression treatment.
See More
Helus Pharma Achieves Breakthrough in Depression Treatment
- Clinical Trial Success: Helus Pharma's SPL026 achieved significant results in a Phase 2 trial for treatment-resistant depression, with a mean MADRS difference of -7.35 (p=0.023) among 34 participants receiving a 21.5 mg dose, indicating strong efficacy and market potential for the drug.
- FDA Breakthrough Therapy: Helus's HLP003 has received FDA Breakthrough Therapy designation and is undergoing two pivotal Phase 3 trials, with early data showing 100% response rates and 71% remission at 12 months, potentially offering new treatment options for depression and solidifying the company's position in the psychiatric drug market.
- Strong Financial Backing: As of December 31, 2025, Helus Pharma reported $195.1 million in cash reserves, providing robust financial support for the continued advancement of its multi-asset clinical pipeline, ensuring the company can maintain its competitive edge in a rapidly evolving market.
- Significant Market Potential: The World Health Organization estimates that depression and anxiety cost the global economy over $1 trillion annually in lost productivity, positioning Helus Pharma's innovative drugs to meet this substantial market demand and drive future growth and investment appeal.
See More
Compass Pathways Exercises Warrants Raising $200 Million
- Warrant Exercise: Compass Pathways exercised 35,059,448 warrants issued on January 13, 2025, generating approximately $200 million, enhancing the company's financial flexibility to support future growth initiatives.
- ADS Issuance Plan: The company plans to issue 15,160,619 American Depositary Shares (ADSs) and provide pre-funded warrants for certain institutional investors to purchase up to 19,898,829 ADSs, further expanding its capital base to support clinical trials.
- Funding for Clinical Trials: The proceeds from this capital raise will fund ongoing Phase 3 trials for COMP005 and COMP006, as well as the Phase 2b/3 trial of COMP360 in PTSD, accelerating commercial readiness activities to maintain a competitive edge in the market.
- Financial Outlook: The net proceeds from the warrant exercises, along with approximately $141 million from a recent public offering, are expected to sufficiently cover operating expenses and capital expenditure needs through 2028, demonstrating the company's robust financial planning capabilities.
See More
Compass Pathways Exercises 35 Million Warrants for $200 Million
- Significant Financing: Compass Pathways exercised 35,059,448 warrants, raising approximately $200 million, which will provide robust funding for its clinical trials and commercial readiness activities, ensuring ongoing innovation in the mental health sector.
- Clinical Trial Funding Assurance: The proceeds will support the Phase 3 trials of COMP005 and COMP006, as well as the Phase 2b/3 trial of COMP360 for PTSD, ensuring progress in critical treatment areas and enhancing market competitiveness.
- Enhanced Financial Stability: Along with approximately $141 million from a recent public offering, Compass Pathways expects sufficient funds to cover operating expenses and capital expenditures into 2028, boosting investor confidence in the company's future growth.
- Innovative Treatment Prospects: COMP360, as a potential first-in-class treatment, has received Breakthrough Therapy designation from the FDA, indicating the company's leading position in mental health treatment and the potential to offer new solutions for patients with treatment-resistant depression.
See More
Helus Pharma Advances New Drug for Anxiety Treatment
- Clinical Trial Progress: Helus Pharma's Phase 2 signal detection study for HLP004 showed that among 36 patients, those receiving 20 mg achieved a mean HAM-A score reduction of 10.4 points (p<0.0001) at six weeks, indicating significant efficacy and potential for new treatment options for anxiety patients.
- Strong Market Demand: The global economy loses over $1 trillion annually due to depression and anxiety, with approximately 30% of patients suffering from treatment-resistant depression, driving the need for novel rapid-acting therapies, which Helus Pharma aims to address.
- Sufficient Financial Support: As of December 31, 2025, Helus Pharma reported $195.1 million in cash, providing ample resources to support the ongoing advancement of its multi-asset clinical pipeline, ensuring the company maintains a competitive edge in a challenging market.
- Strengthened Leadership: Helus Pharma recently appointed former Pfizer Chief Medical Officer Freda Lewis-Hall to its Board of Directors and as Chair of the Scientific Advisory Committee, leveraging her extensive industry experience to further enhance the company's scientific development and market strategy.
See More
Helus Pharma Advances Mental Health Treatments with Promising Phase 2 Results
- Clinical Trial Progress: Helus Pharma's Phase 2 signal detection study for HLP004 showed that patients receiving the 20 mg dose achieved a mean HAM-A score reduction of 10.4 points (p<0.0001) at six weeks, indicating significant efficacy and potential as an adjunctive treatment for generalized anxiety disorder.
- Strong Market Demand: The global economy loses over $1 trillion annually due to depression and anxiety, with approximately 30% of major depressive disorder patients being treatment-resistant, driving urgent demand for novel therapeutic mechanisms that Helus Pharma aims to address.
- Sufficient Financial Support: As of December 31, 2025, Helus Pharma reported $195.1 million in cash, ensuring continued advancement across its multi-asset clinical pipeline and safeguarding its research activities in the mental health sector from financial constraints.
- Enhanced Leadership: The appointment of Dr. Freda Lewis-Hall to Helus Pharma's Board and as Chair of the Scientific Advisory Committee, leveraging her extensive experience at Pfizer, is expected to provide crucial guidance for the company's scientific development and market strategy.
See More
Helus Pharma's Psychedelic Drug Achieves Phase 3 Success
- Clinical Trial Breakthrough: Helus Pharma's SPL026 demonstrated significant efficacy in a randomized controlled trial for treatment-resistant depression, with a MADRS score difference of -7.35 (p=0.023) among 34 participants, providing clinical proof-of-concept that could shift regulatory and investor perspectives on psychedelic applications in psychiatry.
- Production Quota Increase: The DEA raised the 2026 psilocybin production quota by 67%, creating larger market opportunities for companies like Helus Pharma and accelerating their research and development efforts in psychedelic therapies.
- Strong Financial Backing: As of December 31, 2025, Helus Pharma reported $195.1 million in cash, ensuring continued advancement of its multi-asset clinical pipeline, particularly for key assets like HLP003 and HLP004.
- Optimistic Future Outlook: HLP003 has shown a 100% response rate and 71% remission rate in two pivotal Phase 3 studies, with topline data expected in Q4 2026, further solidifying Helus Pharma's market position in depression treatment.
See More
Helus Pharma Achieves Breakthrough in Depression Treatment
- Clinical Trial Success: Helus Pharma's SPL026 achieved significant results in a Phase 2 trial for treatment-resistant depression, with a mean MADRS difference of -7.35 (p=0.023) among 34 participants receiving a 21.5 mg dose, indicating strong efficacy and market potential for the drug.
- FDA Breakthrough Therapy: Helus's HLP003 has received FDA Breakthrough Therapy designation and is undergoing two pivotal Phase 3 trials, with early data showing 100% response rates and 71% remission at 12 months, potentially offering new treatment options for depression and solidifying the company's position in the psychiatric drug market.
- Strong Financial Backing: As of December 31, 2025, Helus Pharma reported $195.1 million in cash reserves, providing robust financial support for the continued advancement of its multi-asset clinical pipeline, ensuring the company can maintain its competitive edge in a rapidly evolving market.
- Significant Market Potential: The World Health Organization estimates that depression and anxiety cost the global economy over $1 trillion annually in lost productivity, positioning Helus Pharma's innovative drugs to meet this substantial market demand and drive future growth and investment appeal.
See More
Compass Pathways Exercises Warrants Raising $200 Million
- Warrant Exercise: Compass Pathways exercised 35,059,448 warrants issued on January 13, 2025, generating approximately $200 million, enhancing the company's financial flexibility to support future growth initiatives.
- ADS Issuance Plan: The company plans to issue 15,160,619 American Depositary Shares (ADSs) and provide pre-funded warrants for certain institutional investors to purchase up to 19,898,829 ADSs, further expanding its capital base to support clinical trials.
- Funding for Clinical Trials: The proceeds from this capital raise will fund ongoing Phase 3 trials for COMP005 and COMP006, as well as the Phase 2b/3 trial of COMP360 in PTSD, accelerating commercial readiness activities to maintain a competitive edge in the market.
- Financial Outlook: The net proceeds from the warrant exercises, along with approximately $141 million from a recent public offering, are expected to sufficiently cover operating expenses and capital expenditure needs through 2028, demonstrating the company's robust financial planning capabilities.
See More
Compass Pathways Exercises 35 Million Warrants for $200 Million
- Significant Financing: Compass Pathways exercised 35,059,448 warrants, raising approximately $200 million, which will provide robust funding for its clinical trials and commercial readiness activities, ensuring ongoing innovation in the mental health sector.
- Clinical Trial Funding Assurance: The proceeds will support the Phase 3 trials of COMP005 and COMP006, as well as the Phase 2b/3 trial of COMP360 for PTSD, ensuring progress in critical treatment areas and enhancing market competitiveness.
- Enhanced Financial Stability: Along with approximately $141 million from a recent public offering, Compass Pathways expects sufficient funds to cover operating expenses and capital expenditures into 2028, boosting investor confidence in the company's future growth.
- Innovative Treatment Prospects: COMP360, as a potential first-in-class treatment, has received Breakthrough Therapy designation from the FDA, indicating the company's leading position in mental health treatment and the potential to offer new solutions for patients with treatment-resistant depression.
See More
